SS
RXRX icon

SBI Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

SBI Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Sell
204,333
-38,284
-16% -$127K 0.02% 337
2026
Q1 		$745K Buy
242,617
+18,693
+8% +$72.2K 0.02% 319
2025
Q4 		$916K Buy
223,924
+95,810
+75% +$475K 0.02% 286
2025
Q3 		$625K Buy
128,114
+3,176
+3% +$16.7K 0.02% 345
2025
Q2 		$632K Buy
124,938
+71,316
+133% +$350K 0.02% 328
2025
Q1 		$284K Buy
53,622
+4,349
+9% +$31.7K 0.01% 443
2024
Q4 		$333K Buy
+49,273
New +$331K 0.01% 422

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities's RXRX Position: Q2 2026 in Review

SBI Securities reduced its Recursion Pharmaceuticals (RXRX) stake by 16% in Q2 2026, selling an estimated $127K and leaving 204,333 shares worth $750K. The position accounts for 0.02% of the portfolio, ranked #337.

SBI Securities first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $916K in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • SBI Securities held 204,333 shares of Recursion Pharmaceuticals worth $750K as of Q2 2026.
  • SBI Securities sold 38,284 Recursion Pharmaceuticals shares in Q2 2026, an estimated $127K.
  • Recursion Pharmaceuticals made up 0.02% of SBI Securities's portfolio in Q2 2026, its #337 holding.
  • SBI Securities first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Recursion Pharmaceuticals position peaked at $916K in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.